Visit the IBD Store to get started.
Biotech Stocks To Watch And Pharma Industry News
- IBD STAFF
One minute Dow Jones industrial average component Merck (MRK) might be doing battle with fellow drugmaker Bristol-Myers Squibb (BMY) over drugs that can ward off cancer.
The next, biotech giants like Amgen (AMGN) and Sanofi (SNY) are tussling in court over the fate of cholesterol-busting drugs. Meanwhile, a company like Gilead Sciences (GILD) might be raked over the coals in Congress for charging $1,000 a day to treat hepatitis.
It’s a brave – and contentious – new world for pharmaceutical and biotechnology companies. It’s a realm where science is trying to develop landmark medicines that cure cancer, hepatitis and other life-threatening illnesses.
All the while it does a delicate dance with Wall Street and regulators – balancing public health issues with the demands of shareholders. Investors will find it tricky to navigate the sector, as companies can rise and fall at the drop of a hat.
Bookmark this page to stay on top of the latest news in the biopharma sector.
Biotech And Pharma News
- IBD STAFF | [email protected]
Which Stocks Are Showing Rising Relative Strength?
11:04 AM ET See which stocks are showing resilience and strength with an IBD RS Rating upgrade.
11:04 AM ET See which stocks are showing resilience and strength with an.
Why Roche Cancer Trial Is Kick In The Teeth For Dow Stock Merck
Stocks Close Modestly Higher As Verizon Helps Prop Up The Dow
IBD Rating Upgrades: Biogen Shows Improved Price Strength
Biotech Industry: Small Innovators Outflank Big Caps As Blockbuster Drug Patent Cliff Looms
This Biotech Just Neared A 17-Year High On Strong Cancer Regimen
Indexes Quiet, Small Caps Recover; 4 Hot Stocks Gap Up In Price
Ionis Shares Dip After Third-Quarter Sales, Earnings Miss
Teva Survives Price Cut As Billionaire Reportedly Mulls Stake
CAN SLIM Masters Program 12/9-12/10
Get the All-New IBD App
Black Friday Deals
- U.S. Business Equipment Orders Fall For First Time Since June
- Is It Too Late To Invest In Surging Biotech, Chip Stocks?
- Get the #1 trading app in the App Store from TD Ameritrade Promoted Content By TD Ameritrade
Which Companies Are Now Outperforming 95% Of All Stocks?
See which stocks just got an upgrade and now have a 95 or higher IBD Composite Rating.
Get instant access to exclusive stock lists, expert market analysis and educational tools with a free trial to IBD Digital.
Get market updates, educational videos, webinars, and stock analysis.
Learn how you can make more money with IBD s investing tools, top-performing stock lists, and educational content.
- Connect With Us On
Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.
*Real-time prices by Bats®. Volume delayed. Real-time quote and/or trade prices are not sourced from all markets.
© 2000-2017 Investor’s Business Daily, Inc. All rights reserved